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Abstract
Immunotherapy has the potential to change the way all cancer types are treated
and cured. Cancer immunotherapies use elements of the patient immune system
to attack tumor cells. One of the most successful types of immunotherapy is
CAR-T cells. This treatment works by extracting patients T-cells and adding
to them an antigen receptor allowing tumor cells to be recognized and targeted.
These new cells are called CAR-T cells and are re-infused back into the patient
after expansion in-vitro. This approach has been successfully used to treat B-cell
malignancies (B-cell leukemias and lymphomas). However, its application to the
treatment of T-cell leukemias faces several problems. One of these is fratricide,
since the CAR-T cells target both tumor and other CAR-T cells. This leads to
nonlinear dynamical phenomena amenable to mathematical modeling.
In this paper we construct a mathematical model describing the competition
of CAR-T, tumor and normal T-cells and studied some basic properties of the
model and its practical implications. Specifically, we found that the model
reproduced the observed difficulties for in-vitro expansion of the therapeutic
cells found in the laboratory. The mathematical model predicted that CAR-T
cell expansion in the patient would be possible due to the initial presence of a
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large number of targets. We also show that, in the context of our mathematical
approach, CAR-T cells could control tumor growth but not eradicate the disease.
Keywords: Mathematical Oncology, T-cell leukemias, CAR-T cell therapies
1. Introduction
Cancer immunotherapies use elements of the patient immune system to at-
tack tumor cells. These treatments encompass different therapeutic strategies
typically involving collecting a specific set of cells from patients, modifying them
to produce some kind of attack on cancer cells, and reinjecting them. Some ex-
amples are tumor-infiltrating lymphocytes, engineered T-cell receptor, chimeric
antigen receptor (CAR)-T cells, cytotoxic T-lymphocytes, natural killer cells,
and mesenchymal stem cells [1].
Of these, the most successful type of immunotherapy today is CAR-T cells.
This treatment works by extracting patients T-cells and adding the CAR group
to them, allowing them to recognize and target the cells carrying an antigen ex-
pressed in the tumor [2]. The case of B-cell leukemias expressing CD19 has been
particularly successful since this antigen is only expressed by B-lymphocytes and
B-lymphoid leukemia cells. The clinical use of CAR-T cells engineered to rec-
ognize this antigen have led to the full recovery of a large fraction of Acute
Lymphoblastic Leukemia patients [2, 3, 4, 5]. Good results have been reported
for large B-cell lymphomas [6, 7] and multiple myelomas [8]. These successes
have led to the approval of CAR-T therapies directed against CD19 for treat-
ment of acute lymphoblastic leukemias and diffuse large B-cell lymphomas [9].
However, CAR-T cell therapies have not yet been as successful for solid tumors,
for a variety of different reasons [10, 11].
Mathematical modeling has the potential to help in finding optimal admin-
istration protocols, provide a deeper understanding of the dynamics, help in
the design of clinical trials and more. The clinical relevance of CAR-T cells
has attracted the attention of applied mathematicians that have started to
construct mathematical models and study different aspects of these therapies
[12, 13, 14, 15, 16, 17].
Given the success of CAR-T cells directed against CD19 in B-cell malignan-
cies, new targets are being developed and tested. Specifically, there has been a
lot of interest in the possibility of using CAR-T cells for the treatment of T-cell
malignancies [18, 19, 21, 22]. However there are many challenges in translating
this therapy for T-cell disease. The first one is fratricide, which refers to the
mutual killing of CAR T-cells. This phenomenon may prevent the generation,
expansion and persistence of CAR-T cells. The second one is the prolonged
and profound T-cell aplasia induced by the destruction of normal T-cells, that
exposes patients to severe opportunistic infections. The third one is the po-
tential contamination of CAR T-cell products with malignant T-cells. Indeed,
circulating tumor T-cells are often found in the peripheral blood of patients.
Because tumor T-cells may harbor the same properties as normal T-cells, they
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may be harvested, transduced, expanded, and infused concomitantly with nor-
mal T-cells as described recently in the context of B-cell leukemias [23]. Thus,
developing CAR-T cells for T-cell malignancies requires avoiding contamination
of the CAR-T cell product with malignant transduced T-cells [18].
To the best of our knowledge, no mathematical model has yet considered
CAR-T cell treatments for T-cell malignancies.
In this paper we want to build the first minimal mathematical model de-
scribing the dynamics of tumor cells in T-cell leukemias and normal T-cells plus
a population of injected CAR-T cells. Our intention is to describe the effect
of the fratricide mathematically and to obtain conclusions of practical interest.
This interesting phenomenon, which involves a nonlinear self-interaction within
the CAR-T cell compartment will be shown to place a limit on the production
of these cells in vitro. Our theoretical and simulation results support that CAR
T-cells could be able to control tumor growth in vivo to a certain extent. We
will show that it may not be possible to get rid of all tumor cells, but that the
treatment could be useful either as a bridge treatment or as a way of making
the disease chronic.
Our focus in this paper was to perform a preliminary exploration of the bio-
logical problem and obtain conclusions of practical applicability, using numerical
simulations of the mathematical model as a test bed.
The structure of the paper is as follows. First, in Sec. 2 we set out the
mathematical model, estimate its parameters and perform a basic study of some
of its properties and study the model’s equilibria. Next, in Sec. 3 we consider
different scenarios including the generation of the CAR-T product in vitro and
the in-vivo dynamics. Finally, Sec. 4 discusses our findings and summarizes our
conclusions.
2. The Model
2.1. Basic Mathematical Model
Our mathematical model accounts for the dynamics of several cell popula-
tions: CAR-T cells C(t), leukemic T-cells L(t), and normal T-cells T (t). The
equations describing the dynamics of these populations are
dC
dt
= ρC (T + L+ C)C − 1
τC
C − αC2 + ρIC, (1a)
dL
dt
= ρLL− αLC, (1b)
dT
dt
= g(T, L,C)− αTC. (1c)
CAR-T cells, described by Eq. (1a), have a finite lifespan τC and prolifer-
ate due to stimulation by target cells (either L(t) or T (t) or the CAR-T cell
themselves C(t)). The parameter ρC measures the stimulation of mitosis after
encounters with target cells. The parameter α in Eq. (1a) is a cell kill term
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accounting for the fratricide. It measures the probability that CAR-T cell en-
counters lead to the death of one of the cells. Once the CAR-T cell identifies the
target cell, killing and detachment are very fast processes [27]. We consider here
only serial killing, excluding multiplexed killing, which would be a less relevant
process and have a different kinetics.
In line with models for CAR-T cell dynamics in B-cell leukemias [17], we did
not include a CAR-T cell death term due to encounters with target cells. The
reason is that CAR-T cells do not die after killing target cells [24, 25]. Also,
T-cells do not divide in vivo spontaneously [26], their clonal expansion being
dependent on the stimulation with the target antigen, thus in vivo ρI = 0. When
CAR-T cells are expanded in-vitro cytokines are added externally forcing the
cells to divide, thus in that context we will assume ρI 6= 0.
Leukemic cells [Eq. (1b)] proliferate with a rate ρL and die to the encounters
with the CAR-T cells with the rate α.
For the normal T-cell compartment we will only consider a simplified effec-
tive description accounting for the different lineages expressing the same target
antigen in an aggregate form. These cells will be assumed to be killed at a rate
α per cell assumed to be similar to that of the other subpopulations and will be
produced at a rate g(T, L,C). This function is expected to depend on the total
number of T-cells via cytokine signaling, on the effect of CAR-T cell on T-cell
progenitors, etc. In this paper we will assume g(T, L,C) to be very small and
contribute only to a minimal residual level of normal T-cells that would not be
relevant for the nonlinear dynamics of the system. In what follows we will take
g(T, L,C) = 0.
Figure 1 summarizes the relationships between the different cell subpopula-
tions and the assumptions behind our model.
2.2. In-vitro equilibria
The in-vitro expansion during the CAR-T cell production can be described
by setting L = T = 0 in Eqs. (1), and taking ρI 6= 0, thus
dC
dt
= ρˆC − αˆC2. (2)
The parameter ρˆ = ρI − 1/τC > 0 always in vitro and the effective cell kill rate
αˆ = α− ρC ≥ 0, since the kill rate is expected to be larger than the stimulation
rate due to the different speeds of the killing and replication processes.
Eq. (2) is a logistic equation, that for positive initial values satisfies that
C −→
t→∞ C∗ = ρˆ/αˆ. (3)
This result is in line with the observation that CAR-T cells targeting T-cell
antigens cannot be expanded beyond a certain value [19]. Here we show that
this value will depend on the cytokine stimulation provided and the fratricidal
cell killing rate.
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Figure 1: Cellular populations and biological processes included in the mathemat-
ical model (1). Normal T (t) and leukemic L(t) T-lymphocytes are killed by CAR-T cells
C(t) at a rate α and stimulate CAR-T cell proliferation at a rate ρC , both per cell. Tumor
lymphocytes proliferate at a rate ρL. As a result of fratricide and self-stimulation, CAR-T
cells are eliminated at a rate α−ρC per CAR-T cell. CAR-T cell finite lifetime τC also results
in cell loss.
2.3. Parameter estimation
Some parameters in model Eq. (1) can be estimated from biological data.
Firstly, the typical lifetime of activated CAR-T cells τc is in the range 14-28
days [20]. T-cell leukemias are typically rather aggressive tumors with small
doubling times that can be estimated to be around ρL = 1/40 day
−1 in vivo
[28], although chronic forms of the disease could have much smaller numbers
[29]. Finally, α and ρC can be expected to be in the range of B-cell leukemias,
where they have been found to be around 10−11 day−1cell−1 [17]. One would
expect ρC to be of the order of or smaller than α, since it corresponds to the
number of new cells generated by each encounter of CAR-T cells with target
cells.
As to the initial data, the total number of T-lymphocytes in the human
body is around 1011 and typical tumor loads in acute T-cell leukemias can be
in a similar range [30]. Most CAR-T administration regimes are preceded by a
lympho-depleting treatment that creates a favorable cytokine profile, favoring
the growth of injected cells [31, 32]. Thus, the previous numbers are substan-
tially reduced once the treatment is started. We will take our initial data to be
around ∼ 1010 for tumor and normal T-cells.
Finally, the number of CAR-T cells injected would depend on the maximal
expansion obtained in vitro, which could range from as low as 104 when fratricide
is present to larger numbers around 107 depending on the strategies used to
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overcome it.
2.4. Large initial data display unbounded dynamics
Theorem 1. For any non-negative initial data (C0, L0, T0) and all the param-
eters of the model being positive, the solutions to Eqs. (1) exist for t > 0, are
non-negative and unique.
Proof. The ODE system (1) has bounded coefficients and the right-hand side
of the system is a continuous function of (C,L, T ), thus the local existence of
solutions follows from classical ODE theory. Since the partial derivatives of the
velocity field are continuous and bounded, uniqueness follows from the Picard-
Lindelof theorem.
Let us rewrite Eqs. (1) when g = 0 as
C˙ = [ρC (T + L+ C)− 1/τC − αC]C, (4a)
L˙ = (ρL − αC)L, (4b)
T˙ = − (αC)T, (4c)
then we may write
C(t) = C0 exp
(∫ t
t0
[
ρCT (t
′) + ρCL(t′) + (ρC − α)C(t′)− 1
τC
]
dt′
)
,(5a)
L(t) = L(t0) exp
(∫ t
t0
(ρL − αC(t′)) dt′
)
, (5b)
T (t) = T (t0) exp
(
−
∫ t
t0
αC(t′)dt′
)
, (5c)
which leads to the positivity of solutions.
Definition. The sum of all cell populations studied will be denoted by S(t), i.e.
S(t) = C(t) + T (t) + L(t).
Theorem 2. Let C(t), L(t), T (t) be solutions of Eqs. (1) with initial data
C(t0) = C0 > 0, L(t0) = L0 > 0, T (t0) = T0 > 0, S(t0) = S0 > 0. If
H1 ρC > α
H2 (ρC − α)τCS0 > 1,
then S(t) increases monotonically with time and limt→∞ S(t) =∞.
Proof. Let us first sum the three equations Eq. (1) to obtain
dS
dt
= (ρC − α)SC − 1
τ
C + ρLL.
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Then, the positivity of L(t) implies that, S defined as the solution of
dS
dt
= (ρC − α)SC − 1
τ
C, (6)
satisfying S(t0) = S0 with C(t0) = C0, is a subsolution of S(t), i.e. satisfying
S(t) < S(t),∀t > t0. Clearly, under our hypothesis
dS
dt
∣∣∣∣
t=t0
=
[
(ρC − α)S0 −
1
τ
]
C0 > 0,
but then, using Eqs. (6), this leads to dS/dt > 0 for all t > t0. Moreover, from
Eq. (1a) and using the fact that S(t) > C(t), for all t > t0 we get
dC
dt
= ρCSC − 1
τC
C − αC2 >
[
(ρC − α)S − 1
τC
]
C, (7)
where we have used ρCSC − 1τCC − αC2 > ρCSC − 1τCC − αC (C + L+ T ).
This means that C(t) > C0 for any non-zero initial data, then
dS
dt
> (ρC − α)S0 −
1
τ
C0 ≡ Q0 > 0, (8)
then S(t) > S(t) > Q0t + S0, which proves the unboundedness of the total
population S(t), i.e. the fact that limt→∞ S(t) =∞.
Taking reasonable initial numbers (see Sec. 2.3) we will always initially be
in the regime (ρC − α)τCS0 > 1.
2.5. Equilibria of the model Eqs. (1) and local stability analysis
The equilibria of Eqs. (1) in the case of interest g = 0, are given by the
equations
0 = ρC (T + L+ C)C − 1
τC
C − αC2, (9a)
0 = ρLL− αLC, (9b)
0 = −αTC. (9c)
Eq. (9c) leads to either T = 0 or C = 0. The latter leads to L = 0 using Eq.
(9b) and the former to either L = 0 or C = ρL/α. Then using Eq. (9a) allows
us to obtain the expressions for the three equilibrium points of Eqs. (1)
E1 = (0, 0, T∗), (10a)
E2 =
(
ρL
α
,
1
ρCτC
+
ρL
ρC
− ρL
α
, 0
)
. (10b)
E3 =
(
1
τc (ρC − α) , 0, 0
)
. (10c)
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for any T∗. The Jacobian of the differential equations (1) is
J =
 2 (ρC − α)C − 1/τC + ρC (T + L) ρCC ρCC−αL ρL − αC 0
−αT 0 −αC
 . (11)
Let us now use Eq. (11) to study the local stability of the different equilibria
given by Eqs. (10). Firstly, for E1 we get
J (E1) =
 ρCT∗ − 1/τC 0 00 ρL 0
−αT∗ 0 0
 . (12)
The eigenvalues of J (E1) are
λ1 = 0, λ2 = ρL, λ3 = ρCT∗ − 1/τC , (13)
thus the equilibrium point E1 is unstable. For the second equilibrium point we
get
J (E2) =
 ρL (ρCα − 1) ρCρL/α ρCρL/α−α (ρL + 1/τC) /ρC + ρL 0 0
0 0 −ρL
 . (14)
Thus λ3 = −ρL < 0 and λ1,2 satisfy the equation
λ2 + λ
(
1− ρC
α
)
ρL + ρ
2
L
(
1− ρC
α
)
+
ρL
τ
= 0, (15)
which leads to the eigenvalues
λ± =
1
2
ρL
(ρC
α
− 1
)
± 1
2
D1/2, (16)
with the discriminant D being given by
D
ρ2L
=
(
1− ρC
α
)2
− 4
(
1− ρC
α
)
− 4
ρLτC
. (17)
Let us consider the case ρC/α < 1 since the system will be unstable otherwise
(Sec. 2.4). Then,
0 < 1− ρC
α
< 1.
Since (1− ρC/α)2 < 1− ρC/α, we get
D
ρ2L
< −3
(
1− ρC
α
)
− 4
ρLτC
< 0.
Thus, the equilibrium is a stable node-focus.
Finally, for E3 we get
J(E3) =
1
τC
 1 ρCρC−α ρCρC−α0 ρLτc + αα−ρC 0
0 0 αα−ρC
 . (18)
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The eigenvalues of J(E3) are
λ1 = 1/τC > 0, (19a)
λ2 = ρLτc + α/(α− ρC) > 0, (19b)
λ3 = α/(α− ρC) > 0, (19c)
thus E3 is an unstable node.
In conclusion, there is only one stable equilibrium point E2 given by Eqs.
(10) of node-focus type, which can be an attractor for the dynamics of the
system (1).
3. Applications.
3.1. CAR-T cells allow for control of T-cell leukemias in the presence of fratri-
cide
To obtain further insight into the global dynamics of solutions of Eqs. (1)
we simulated different initial data in the biologically feasible parameter and
initial data regions. In all cases studied, we found an oscillatory behavior of the
solutions towards the stable node-focus point E2 after a fast reduction of the
initial normal T-cell number.
Figure 2 provides a typical example of the dynamics. There we see how
tumor grows for a short time, typically 10-15 days, while CAR-T cells expand.
The CAR-T cell expansion persists over more than four orders of magnitude in
cell number (Figure 2(c)), with a peak at about 15 days after injection (Figure
2(b)). This leads to a substantial decrease of the tumor load and T-cell aplasia
(Figure 2(a,b)). For this parameter set, tumor was not controlled for long
periods of times and relapse was noticeable a few months after the injection
date of CAR-T cells. After relapse oscillations of leukemic and CAR-T cells are
observed in their course towards the equilibrium, in this case corresponding to
3 × 108 CAR-T cells and 2.7 × 109 tumor cells. Interestingly, the number of
tumor cells in this case is one order of magnitude smaller than the initial tumor
load (2 × 1010 cells), which supports the possibility of CAR-T cells effectively
controlling tumor to clinically acceptable levels.
The numerical results used to construct Figure 2(c), show that in less than
two months after injection, treatment was able to reduce tumor load from the
initial level of 2× 1010 cells down to a minimum level of 2.59× 108 cells, i.e. a
decrease of about two orders of magnitude.
3.2. Higher mitotic stimulation rates improve tumor control
The asymptotic equilibrium values of leukemic cells and CAR-T cells are
given by E2, i.e.
L2 =
1
ρC
(
ρL +
1
τC
)
− ρLρC
α
, (20a)
C2 =
ρL
α
. (20b)
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Figure 2: Typical dynamics of cell populations governed by Eq. (1). Results of a
simulation are shown for parameter values τC = 14 days, ρL = 1/60 day
−1, α = 5.84× 10−11
day−1 cell−1, ρC = α/2, and initial data T0 = 109, L0 = 2 × 109, C0 = 105 cells. (a-
c) Dynamics of the populations of CAR-T (green), tumor (red) and normal T cells (blue).
Dynamics are depicted on the time intervals t ∈ [0, 1200] (a,c) and t ∈ [0, 50] (b) , and in
linear (a,b) and logarithmic (c) scales. (d) Trajectory of the solution in the phase space. (e)
Projection of the selected part of the trajectory on the (T (t), C(t)) plane.
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Figure 3: Higher mitotic stimulation rates provide better tumor control. Dynamics
of the leukemic population governed by Eq. (1) for initial data T0 = 109, L0 = 2× 109, C0 =
105 cells, and parameter values τC = 14 days, ρL = 1/60 day
−1, α = 5.84 × 10−11 day−1
cell−1. The different curves correspond to stimulation rates ρC = 0.2α (blue solid line),
ρC = 0.4α (red dashed line), ρC = 0.6α (green, dash-dotted line), ρC = 0.8α (black dotted
line).
Interestingly, the equilibrium level of CAR-T cells does not depend on the mi-
totic stimulation rate ρC , but only on the growth and death rates of leukemic
cells. However, the most important thing, due to the clinical implications, are
the leukemia equilibrium levels L2, and the maximum leukemic load maxt L(t).
Maxima would typically be attained in time during the CAR-T cell expansion
stage.
Let us note that
dL2(ρC)
dρC
= − 1
ρ2C
(
ρL +
1
τC
)
− ρL
α
< 0, (21)
this means that L2(ρC) is a monotonically decreasing function. Since ρCα > 0,
the minimum of L2(ρC) over the range ρC ∈ [0, α] would be obtained when
ρC = α. Figure 3 confirms that the asymptotic values of L2 decrease with the
mitotic stimulation rate ρC and thus larger values of the mitotic stimulation
rate lead to better tumor control. However, going beyond ρC = α destabilizes
the system, as discussed in Sec. 2.4. Thus, it may be necessary to control in
detail the CAR-T manufacturing process to get both high mitotic stimulation
rates while at the same time not getting too close to the instability regime.
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3.3. Initial number of CAR-T cells injected does not affect the outcome of ther-
apy
We next studied the effect of the number of CAR-T cells initially injected
on the system’s dynamics. To do so, we performed an extensive number of sim-
ulations over the biologically feasible range and found a very weak dependence
of the dynamics on the number of injected CAR-T cells. An example is shown
in Fig. 4 for a broad range of cells initially injected ranging from 104 to 106.
Although there was a difference of two orders of magnitude in C0, it led to a
small variation in the time to peak expansion of a few days, a negligible increase
of the maximum CAR-T and leukemic cell number, and a minor differences in
the times to tumor relapse.
3.4. Tumor proliferation rate did not essentially affect either the initial response
or the asymptotic leukemic cell values, but did influence relapse time
Finally, we studied the dynamics under modifications of the tumor prolifera-
tion rate in the whole feasible range for fast-growing leukemias ρC ∈ [1/60, 1/20].
The result of typical simulations are shown in Figure 5.
The short term dynamics in response to the CAR-T injection were found
to be qualitatively similar independently of the tumor proliferation rate, with a
peak tumor cell number around day 10 post-injection (Figure 5(b)). Small dif-
ferences were observed in the peak number of tumor cells obtained, essentially
due to the fact that faster growing leukemic cells could grow further during
the initial CAR-T expansion phase. After CAR-T cell expansion, there was a
response phase for the different tumor growth speeds and then a relapse was ob-
served (Figure 5(a)). The relapse time was found to depend on the proliferation
rate. This is in line with what one would expect for the amplitude and frequency
of oscillations towards the equilibrium point E2, which are both proportional to
ρL according to Eq. (16).
As expected from the expression for E2, and the values of the parameters,
there was a weak dependence of the number of leukemic cells in the equilibrium
on ρL in the range of relevance (Figure 5(c)), given analytically by L2 = 1.5289×
109+4.2808×109ρL, with ρL ∈ [1/60, 1/20] day−1. Thus the major contribution
to the asymptotic tumor cell count was L2 ∼ 1/(ρCτC).
Although the therapy had a substantial effect, logarithmic scale plots (Figure
5d) show the persistence of measurable disease for all times.
Let us define the maximum tumor cell load reduction achieved by the treat-
ment as
R = max
t
(T (t)) /min
t
(T (t)) . (22)
In the simulations shown in Figure 5, this quantity was found to be R(ρL =
1/20) = 65, R(ρL = 1/30) = 72, R(ρL = 1/40) = 78, R(ρL = 1/50) = 82,
R(ρL = 1/60) = 88, thus always smaller than 100 (two orders of magnitude).
It is easy to see that CAR-T cells decreased in number over time, as did the
tumor load, but they were always above the numbers of cells initially injected.
In fact, for most tumor proliferation rates the number of CAR-T cells was more
than one order of magnitude above the level injected.
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Figure 4: Initial number of CAR-T cells injected does not affect the outcome of
therapy. Dynamics of the number of CAR-T cells (a,b) and leukemic cells (c,d) governed by
Eq. (1) over the time range [0,300] days (a,c). We also show the details of the initial response
of the treatment over the time interval [0,30] (b,d). Initial data used in the simulations
were T0 = 109, L0 = 2 × 109 cells, and parameter values τC = 14 days, ρL = 1/60 day−1,
α = 5.84× 10−11 day−1 cell−1. The curves correspond to different values of C0 = 104 (blue
solid line), C0 = 105 (red dashed line), C0 = 106 (green dash-dotted line).
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Figure 5: Tumor proliferation rate did not affect either the initial response or
the asymptotic values, but did influence relapse time. Dynamics of the leukemic
population governed by Eq. (1) for initial data T0 = 109, L0 = 2 × 109, C0 = 105 cells, and
parameter values τC = 14 days, α = 5.84 × 10−11 day−1 cell−1, ρC = 0.5α, for different
values of ρL. The different curves correspond to different values of ρL = 1/60 (blue line),
ρL = 1/50 (red line), ρL = 1/40 (green line), ρL = 1/30 (magenta line), ρL = 1/20 (cyan
line) (a) Dynamics over the time range [0,800] days. (b) Details of the dynamics for the time
interval [0,25]. (c) Dependence of the asymptotic tumor values obtained from Eq. (20a). (d)
Tumor cell number evolution in logarithmic scale. The rate between maximum and minimum
tumor load is indicated with an arrow for the case ρL = 1/20. (e) Evolution of the number of
CAR-T cells.
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Figure 6: CAR-T cell reinjection does not improve the therapy outcome. Variations
of the maximum tumor load at the first relapse when reinjecting C = 105 CAR-T cells for
different reinjection times using initial data T0 = 109, L0 = 2 × 109, C0 = 105 cells, and
parameter values τC = 14 days, α = 5.84 × 10−11 day−1 cell−1, ρC = 0.5α. The different
curves correspond to different values of the tumor proliferation rate ρL = 1/60 (blue line),
ρL = 1/50 (red line), ρL = 1/40 (green line), ρL = 1/30 (magenta line), ρL = 1/20 (cyan
line).
3.5. CAR-T cell reinjection does not improve the therapy outcome.
An interesting question is if one could control relapses by acting on the tumor
by reinjecting CAR T cells. To study that we performed extensive numerical
simulations over the parameter range of interest. Figure 6 summarizes some
results where we simulated the reinjection of C = 105 CAR-T cells at different
times post-injection for different tumor growth rates and quantified the varia-
tions in maximum tumor load with respect to the case without reinjection. In
the best scenario, corresponding to slowly growing tumors, the improvement
in the peak tumor cell number at relapse was around 2%. Thus, the CAR-T
reinjection did not substantially improve the outcome for any delay nor tumor
proliferation rate.
4. Discussion and Conclusion
CAR-T cell therapies for B-cell malignancies is one the most resounding
successes of the current immunotherapies, driving a strong interest on the topic
[9]. Several mathematical models have been constructed describing the observed
dynamics [12, 13, 14, 15, 16, 17]. This has lead to very considerable interest
in extending these therapies to other hematological tumors, such as malignant
T-cell leukemias.
As stated in the introduction, one of the challenges faced by these treatments
is fratricide, i.e. the fact that CAR-T cells, belonging to the T-cell lineage and
expressing common antigens with the leukemic cells, would themselves become
targets of the therapy. This poses the very interesting question of what the
outcome of such a therapy would be, given that it poses challenges even for
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CAR-T cell production in vitro. Interestingly, our simple mathematical model
captured the difficulties for CAR-T cell expansion in vitro, with a limit in cell
production given by Eq. (3). Thus, the maximum number of CAR-T cells that
can be produced in vitro depends on the stimulation provided by the cytokines
and the excess CAR-T killing efficiency over the mitotic stimulation.
One might naively think that in-vivo expansion would also be limited, not
having a substantial effect on the disease. However, this is not true. Our
simulations showed that when they are injected, even in the small numbers that
can be obtained in vitro, the CAR-T cells find many targets initially on both
the healthy and tumor T-cells. During this initial stage, the CAR-T population
is amplified even in the presence of fratricide. We also found in silico that the
outcome of the therapy did not depend on the number of CAR-T cells injected.
A relapse was always observed in the framework of our model simulations
and the number of tumor cells was initially reduced by a factor smaller than 100,
with the persistence of measurable disease for all times, so the treatment did
not eradicate the disease in our numerical simulations. However, CAR-T cells
were able to control tumor growth after two weeks and then, even in spite of
the oscillations, the high initial tumor loads were never found to appear again..
Relapse time after the CAR-T treatment was found to depend strongly on
the proliferation rate. This makes us wonder if a combination with a post-CAR
chemotherapy could prove useful in delaying tumor regrowth. The opposite
strategy, i.e. first giving chemotherapy and then CAR-T before relapse, would
not be recommended, however, since chemotherapy would be expected to reduce
the number of target cells and then CAR-T would lack the substrate to expand.
Another question related to these treatments is whether re-challenging with
CAR-T cells at any given time could be beneficial. For instance one may wonder
if that process could be used to delay or even eliminate tumor relapse. On the
basis of our computational results, additional injections were found to have no
substantial effect on the dynamics. The reason is that CAR-T cells decreased in
number transiently in time after reaching peak expansion, but their levels were
always above the numbers of cells initially injected, typically by more than an
order of magnitude. This means that injecting small numbers of CAR-T cells
in relation to those already present would not have a substantial effect on the
dynamics.
The fact that the equilibrium L2 ∼ 1/(ρCτC) implies that there are two ways
to improve the long-term efficacy of CAR-T cell therapy for T-cell leukemias.
The first would be to improve the persistence of the CAR-T cells, something
that has been done for B-cell leukemias by using CD19 CAR (CAT) with lower
affinity than FMC63, the high-affinity binder used in many clinical studies [20].
The second would be to improve the mitotic stimulation rate, but keeping in
mind the restriction α > ρC .
In conclusion, in this paper we have developed a mathematical model of the
dynamics of leukemic cells, healthy T-cells and CAR-T cells, after the ther-
apeutic injection of the latter population. The mathematical model showed
the potential of the treatment to control, but not eradicate, the disease. This
would result in a chronification of the disease that could last for a long time, or it
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could buy some time to try alternative therapeutic strategies. Our work is a first
simple mathematical attempt to cast light on the potential outcomes of these
treatments. There are different types of T-cell malignancies and specifically T-
cell leukemias, and the particular features of each type could be incorporated
into more detailed models including additional biological details. We hope our
work will stimulate further work in this exciting sub-field of immunotherapy.
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